Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Sign Up to like & getrecommendations! Published in 2017 at "Seminars in arthritis and rheumatism"
DOI: 10.1016/j.semarthrit.2017.03.008
Abstract: OBJECTIVE The Italian board for the TAilored BIOlogic therapy (ITABIO) reviewed the most consistent literature to indicate the best strategy for the second-line biologic choice in patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic… read more here.
Keywords: biologic therapy; anti tnf; line biologic; arthritis ... See more keywords
Two‐year persistence of golimumab as second‐line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real‐life data from the LORHEN registry
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.13199
Abstract: To evaluate the 2‐year retention rate of golimumab compared with etanercept and adalimumab as second‐line biologic agent in rheumatoid arthritis (RA) patients who failed a previous tumor necrosis factor inhibitor (TNFi). read more here.
Keywords: agent rheumatoid; line biologic; rheumatoid arthritis; tumor necrosis ... See more keywords
Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK
Sign Up to like & getrecommendations! Published in 2022 at "Frontline Gastroenterology"
DOI: 10.1136/flgastro-2021-101995
Abstract: Background Anti-tumour necrosis factor (anti-TNF) therapies are the most commonly used biologics for inflammatory bowel disease (IBD), but for patients with a comorbidity, newer agents may be a more appropriate treatment choice. Aims To investigate… read more here.
Keywords: disease; line biologic; first line; biologic prescribing ... See more keywords